PARKHOSPS
PARKHOSPS · NSE
₹238.05
+0.41% (+₹0.97)
Prev. close
₹237.08
Volume
2,62,559
Delivery %
48.7%
As of
20 Nov 2026
Price history
Emkay Global Financial Services Analysis · Emkay Global Financial Services · 06 Aug 2026, 14:38 IST
“Maintains a 'BUY' rating on Park Medi World, revising its June-27 price target up by 7% to ₹375 from ₹350, based on 21x June-28E EV/EBITDA. The brokerage highlights strong Q1FY27 performance with 19%/20% yoy revenue/EBITDA growth, agile acquisition playbook, focus on profitability, and ramp-up of new units. Expects 25% revenue CAGR over FY26-29E with ~1.8k bed additions over the next 18 months.”
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Park Medi World, seeing an 83.7% upside potential with a target price of ₹406 in 18-24 months. The brokerage …” | Ventura AnalysisVentura | Park Medi World Ltd | PENDING | ||||
| “Maintains a 'BUY' rating on Park Medi World, revising its June-27 price target up by 7% to ₹375 from ₹350, based on 21x …” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Park Medi World | PENDING | ||||
“Maintains a 'BUY' rating on Park Medi World, revising its June-27 price target up by 7% to ₹375 from ₹350, based on 21x June-28E EV/EBITDA. The brokerage highlights strong Q1FY27 performance with 19%/20% yoy revenue/EBITDA growth, agile acquisition playbook, focus on profitability, and ramp-up of new units. Expects 25% revenue CAGR over FY26-29E with ~1.8k bed additions over the next 18 months.” How this call is judged A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No entry price is stated, so the call starts at the first close after it was published. Target ₹375, as stated. Window: 328 days, the time frame the call states ("June-27"). Window still open: no verdict until a close reaches a level or the window ends. | |||||||
| “Bullish on Park Medi World, setting a long-term target of ₹350. This outlook is driven by management's plan to expand ca…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Park Medi World | PENDING | ||||
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Park Medi World from a medium-to-long-term perspective, despite its muted debut. The company's focus on Tier-…” | Shivani NyatiSwastika Investmart Ltd. | Park Medi World | — |
About Park Medi World Limited
Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone marrow transplant, iMARS / robot-assisted surgery. It also offers bariatric surgery, anaesthesiology, critical care, chest and respiratory diseases, dental care, dermatology, endocrinology, paediatrics, internal medicine and geriatrics, rheumatology, ENT, ophthalmology, obstetrics and gynaecology, interventional radiology and imaging, psychiatry, pathology and microbiology, paediatric surgery, fertility management, nuclear medicine services. It operates NABH accredited multi-super specialty hospitals under the Park brand name. Park Medi World Limited was founded in 2005 and is headquartered in Gurugram, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Sanjay Sharma
Headquarters
Gurugram
Employees
6,423
Website
parkhospital.inExchange
View on NSE ↗Key stats
Market cap
₹9,953.85 Cr
P/E ratio (TTM)
35.1
Dividend yield
0.00%
EPS (TTM)
₹6.57
Beta (1Y · daily vs NIFTY 50)
0.80
Shares float
6.71 Cr
EPS · quarter ended Jun 2026
₹2.05
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹1,252.38 Cr | ₹1,229.06 Cr | ₹1,391.79 Cr | ₹1,679.36 Cr | |
EBITDA | ₹404.74 Cr | ₹338.27 Cr | ₹402.15 Cr | ₹475.93 Cr |
| ₹219.67 Cr | ₹153.49 Cr | ₹201.64 Cr | ₹258.12 Cr | |
Diluted EPS | ₹5.09 | ₹3.55 | ₹4.67 | ₹6.87 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2026 could not be checked against the company's own annual report: this page shows ₹258.12 Cr while the annual report gives ₹36.62 Cr (85.8% apart).
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹1,592.82 Cr | ₹1,912.10 Cr | ₹2,139.22 Cr | ₹2,813.15 Cr | |
| ₹575.68 Cr | ₹686.71 Cr | ₹682.07 Cr | ₹364.19 Cr | |
Stockholders' equity | ₹686.56 Cr | ₹882.80 Cr | ₹1,052.09 Cr | ₹2,021.98 Cr |
CWIP, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹195.03 Cr | ₹361.44 Cr | ₹215.38 Cr | ₹329.09 Cr | |
Investing cash flow | ₹-179.63 Cr | ₹-254.55 Cr | ₹-100.15 Cr | ₹-333.45 Cr |
| ₹1.51 Cr | ₹-130.30 Cr | ₹-88.86 Cr | ₹120.84 Cr | |
Capital expenditure | ₹-98.43 Cr | ₹-71.45 Cr | ₹-145.12 Cr | ₹-119.69 Cr |
End cash position | ₹100.05 Cr | ₹76.63 Cr | ₹103.00 Cr | ₹236.85 Cr |
Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 25–Jun 26(4Q) |
|---|---|
| Promoter | 82.89% |
| Public | 17.11% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Park Medi World Limited | ₹9,659.70 Cr | ₹230.45 | 34.0 | 4.78 | 12.8% | 0.18 | +18.6% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices
Park Medi World Posts Record FY26 Revenue and Profit; Targets 5,740-Bed Network by March 2028
Park Medi World Limited posted its strongest FY26 results, with revenue up 21% to ₹1,679.4 crore and profit after tax rising 27% to ₹273.6 crore, driven by higher occupancy, increased ARPOB and disciplined cost management. The company now aims to expand its bed network to 5,740 by March 2028 through acquisitions, greenfield projects and operating‑and‑managing arrangements across six states.
Park Medi World Shares Tumble As Q2 Profit Falls 30%, Margins Contract On Expansion Costs
BW Businessworld · 6 days ago